Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia
Effective Adjunctive Use of Pergolide With Risperidone for Cognitive Impairment and Negative Symptoms in Schizophrenia
Sponsor: Hamamatsu University
Listed as NCT00197483, this observational or N/A phase trial focuses on Cognitive Impairments and Negative Symptoms and remains suspended. Sponsored by Hamamatsu University, it has been updated 5 times since 2003, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Suspended
-
Jul 2024 — Sep 2024 [monthly]
Suspended
-
Jan 2021 — Jul 2024 [monthly]
Suspended
-
Apr 2018 — Jan 2021 [monthly]
Suspended
Phase: PHASE2 → None
-
Jan 2017 — Apr 2018 [monthly]
Suspended PHASE2
First recorded
Mar 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hamamatsu University
For direct contact, visit the study record on ClinicalTrials.gov .